Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, PK/PD of BIA 5-1058 in Healthy Male Volunteers
NCT02151994Phase 1Completed
- Sponsor
- BIAL
- Start
- Mar 2011
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of zamicastat in hypertension (HTN) and chronic heart failure (CHF) (5 arms), sponsored by BIAL. Primary endpoints: Percentage of Subjects With Treatment-Emergent Adverse Event Related to Study Medication - Single Ascending Dose Period, Percentage of Subjects With Treatment-Emergent Adverse Event Related to Study Medication - Multiple Ascending Dose Period and 1 more. Started Mar 2011; status: completed.
02
Drugs
zamicastat
03
Conditions
hypertension (HTN)chronic heart failure (CHF)
Beyond the preview
Go deeper on NCT02151994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02151994.